Evidence map›Paper›PMID 41150423›Full record

ArticleVaccines2025

Real-World Effectiveness of Racotumomab as Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.

Sailyn Alfonso Alemán, Haslen Cáceres Lavernia, Kirenia Camacho Sosa, Soraida C Acosta Brooks, Orestes Santos Morales, Carmen E Viada González, Meylán Cepeda Portales, Mayelín Troche Concepción, Loipa Medel Pérez, Leticia Cabrera Benítez and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sailyn Alfonso AlemánCelestino Hernández Robau, Medical Oncology, Santa Clara 50100, Cuba.
Haslen Cáceres LaverniaHermanos Ameijeiras Hospital, Medical Oncology, Havana 10348, Cuba.
Kirenia Camacho SosaFaustino Pérez Hospital, Medical Oncology, Matanzas 40100, Cuba.
Soraida C Acosta BrooksSaturnino Lora Hospital, Medical Oncology, Santiago de Cuba 90100, Cuba.
Orestes Santos MoralesCenter of Molecular Immunology, Clinical Direction, Ave 216, Esq. 15, Atabey, Playa, Havana P.O. Box 16040, Cuba.ORCID 0000-0002-9468-8402
Carmen E Viada GonzálezCenter of Molecular Immunology, Clinical Direction, Ave 216, Esq. 15, Atabey, Playa, Havana P.O. Box 16040, Cuba.
Meylán Cepeda PortalesCenter of Molecular Immunology, Clinical Direction, Ave 216, Esq. 15, Atabey, Playa, Havana P.O. Box 16040, Cuba.
Mayelín Troche ConcepciónCenter of Molecular Immunology, Clinical Direction, Ave 216, Esq. 15, Atabey, Playa, Havana P.O. Box 16040, Cuba.
Loipa Medel PérezCenter of Molecular Immunology, Clinical Direction, Ave 216, Esq. 15, Atabey, Playa, Havana P.O. Box 16040, Cuba.
Leticia Cabrera BenítezCenter of Molecular Immunology, Clinical Direction, Ave 216, Esq. 15, Atabey, Playa, Havana P.O. Box 16040, Cuba.
Milagros C Domecq SalmónCenter of Molecular Immunology, Clinical Direction, Ave 216, Esq. 15, Atabey, Playa, Havana P.O. Box 16040, Cuba.
Daymys Estévez IglesiasCenter of Molecular Immunology, Clinical Direction, Ave 216, Esq. 15, Atabey, Playa, Havana P.O. Box 16040, Cuba.
Mayra Ramos SuzarteCenter of Molecular Immunology, Clinical Direction, Ave 216, Esq. 15, Atabey, Playa, Havana P.O. Box 16040, Cuba.ORCID 0000-0002-9058-3224
Tania Crombet RamosCenter of Molecular Immunology, Clinical Direction, Ave 216, Esq. 15, Atabey, Playa, Havana P.O. Box 16040, Cuba.ORCID 0000-0002-2550-7292

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvanced non-small cell lung cancer (NSCLC) has limited curative options and poor survival. Racotumomab, an anti-idiotype monoclonal antibody vaccine targeting tumor gangliosides, has shown efficacy in clinical trials. This study evaluated its real-world effectiveness as maintenance therapy following first-line chemotherapy. MATERIALS AND

methodsA multi-center observational study was conducted on 162 patients with advanced NSCLC who received racotumomab from 2012 to 2024. Effectiveness was evaluated in the intention-to-treat (ITT) cohort. Overall survival (OS) was estimated, with subgroup analyses conducted according to clinical and demographic factors.

resultsThe median OS was 14.9 months (95% CI: 11.7-18.1), and the 5-year survival rate reached 20%. Patients diagnosed with stage III disease, those with better Eastern Cooperative Oncology Group (ECOG) performance status, and individuals younger than 65 years experienced significantly longer survival. Racotumomab demonstrated a favorable hazard ratio compared to historical controls (HR 0.44 vs. supportive care; HR 0.55 vs. docetaxel).

conclusionsIn the era of immune checkpoint inhibitors, these real-world results indicate a promising role for racotumomab in the maintenance setting for advanced NSCLC. These findings provide a strong rationale for further investigation of racotumomab in the context of modern immunotherapy, particularly in combination trials with other immunomodulatory antibodies, along with the validation of clinical and biologic predictive biomarkers.

Indexed as

anti-idiotypic vaccinecancer vaccineNSCLCracotumomabreal world data

Identifiers

PMID41150423
PMCPMC12568215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.